💊 ยา A-Z 🧬 เป้าหมาย 🛠 เครื่องมือ 📚 คู่มือ
ยาทั้งหมด หมวดหมู่ยา ด้านการรักษา ผลข้างเคียง
คู่มือ อภิธานศัพท์ ไทม์ไลน์
การเปรียบเทียบ เส้นทางของยา กลุ่มยา
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Didanosine

CHEMBL1460 Phase 4 ได้รับการอนุมัติ Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
236.2 g/mol
LogP
-1.2
Phase
4

A nucleoside reverse transcriptase inhibitor (NRTI) used as part of combination antiretroviral therapy for HIV infection by blocking the viral enzyme reverse transcriptase needed to make copies of the virus. It must be taken on an empty stomach for adequate absorption. Serious risks include pancreatitis and peripheral neuropathy, and it should not be combined with certain other antivirals.

น้ำหนักโมเลกุล

236.2300 g/mol

LogP

-1.20

TPSA

88.70 Ų

Lipinski RO5

ผ่าน

ด้านการรักษา

Cardiovascular Disease Lymphoma HIV/AIDS Hepatitis C Tuberculosis

กลไกการออกฤทธิ์

Incorporated into viral DNA by reverse transcriptase as a nucleoside analog, causing chain termination and inhibition of viral replication.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

กลไก

Incorporated into viral DNA by reverse transcriptase as a nucleoside analog, causing chain termination and inhibition of viral replication.

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
O=c1[nH]cnc2c1ncn2[C@H]1CC[C@@H](CO)O1

                

                

                
                

                    
InChI

                    
InChI=1S/C10H12N4O3/c15-3-6-1-2-7(17-6)14-5-13-8-9(14)11-4-12-10(8)16/h4-7,15H,1-3H2,(H,11,12,16)/t6-,7+/m0/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C10H12N4O3

                    

                    
                    

                        
HBD / HBA

                        
2 / 5

                    

                    
                    

                        
พันธะที่หมุนได้

                        
2

                    

                    
                    
                    

                        
อะตอมหนัก

                        
17

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
คำถามที่พบบ่อย

                

                    
                    

                        
                        

                            
A nucleoside reverse transcriptase inhibitor (NRTI) used as part of combination antiretroviral therapy for HIV infection by blocking the viral enzyme reverse transcriptase needed to make copies of the virus. It must be taken on an empty stomach for adequate absorption. Serious risks include pancreatitis and peripheral neuropathy, and it should not be combined with certain other antivirals.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Incorporated into viral DNA by reverse transcriptase as a nucleoside analog, causing chain termination and inhibition of viral replication.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Didanosine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL1460.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 135398739.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
ข้อจำกัดความรับผิดชอบทางการแพทย์

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.